Adjuvant trastuzumab unjustified in patients with lower-risk disease.

Zdroj: PharmacoEconomics & Outcomes News. 1/21/2012, Issue 645, p4-4. 1/4p.
Databáze: Academic Search Ultimate
Externí odkaz: